

A decorative graphic in the top left corner consisting of a blue 'L' shape and a green leaf-like shape overlapping it.

April 15, 2016

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip code: 512529

Dear Sir/ Madam,

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Scrip code: SEQUENT

Sub: Press release of the Company titled "Alivira to acquire controlling interest in Interchange Brazil forays into Brazil, the third largest Veterinary Market"

We are pleased to enclose hereby a press release of the Company titled "**Alivira to acquire controlling interest in Interchange Brazil forays into Brazil, the third largest Veterinary Market**" along with Disclosure as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your kind information.

Thanking you,

Yours faithfully,

For Sequent Scientific Limited


Preetham Hebbar
Company Secretary



SeQuent Scientific Limited

Corporate Office : Star II, Opp. IIM, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India. Tel: +91 80 6784 0340 Fax: +91 80 6784 0400

Regd. Office : 301, 3rd Floor, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Indl. Estate, Thane (W), Mumbai - 400 604, India. Tel: +91 22 4111 4777 Fax: +91 22 4111 4754

CIN : L99999MH1985PLC036685 | Email : info@sequent.in | www.sequent.in

Alivira to acquire controlling interest in Interchange Brazil Forays into Brazil, the third largest veterinary market

Mumbai, April 15, 2016 SeQuent Scientific Limited today announced that its subsidiary Alivira Animal Health Limited (Alivira) has signed a definitive agreement to acquire 70% stake in Interchange Indústria e Comércio de Produtos Veterinários S.A. Brazil ("Interchange Brazil")

The transaction is expected to close in the current quarter and subject to customary closing conditions and approval of the competent courts in Brazil. The acquisition will be made through a step down subsidiary in Brazil of Alivira Ireland, a wholly owned subsidiary of the Company.

Strategic Benefits

- Brazil is the third largest veterinary market in the World accounting for 7.5% of the global animal health business. Estimated at \$1.2bn in 2015, Brazilian veterinary market is growing at 10.5% which is twice the average global veterinary growth.
- Brazil has the largest commercial bovine herd. It is number two in poultry market and has the fourth largest swine population in the world.
- Interchange, operating under the trade-name Evance is amongst the 'Top 10' Brazilian Companies operating in the veterinary health space with a focus on poultry and swine segments. The company was founded in 1995 and operates from a modern production plant, meeting the good manufacturing practices required by the Ministry of Agriculture in Brazil.
- The company has a portfolio of over 25 registered products consisting of antimicrobials, parasiticides, sanitizers and products for therapeutic support.
- Interchange's current management team is led by Mr. Jose Nunes Filho, a person of eminence in the Brazilian market with over 40 years of experience in the animal health market.
- The Company registered sales of \$5.8mn in 2015 with an EBITDA of 4%. As part of the transaction, Alivira will invest \$3.6mn to acquire 70% stake in the company, of which \$2.2mn would be fresh infusion into the company to accelerate growth.

Commenting on the development, **Mr. Manish Gupta, Managing Director of Alivira** said "We are pleased to acquire a strategic stake in Interchange/Evance which is an excellent fit to pursue our vision of building a global animal health business. This provides us a foot-hold in the hugely attractive and fast growing Brazilian market. The transaction also allows us access to a strong, professional management team who will help us expand our footprint in the Latam markets".

For Sequent Scientific Limited


Preetham Hebbar
Company Secretary

Mr. Jose Nunes Filho, Chief Executive Officer of Interchange/Evance said *"We are happy with the partnership with Alivira and the capital infusion in to the company for growth. We see a very strong synergy with Alivira with introduction of new products and technologies as well as giving us access to low cost raw materials. We are confident that this partnership will fast track the growth of Evance and reach an outstanding position in the Brazilian market "*.

About Alivira Animal Health Limited

Alivira Animal Health Limited ("Alivira") is a vertically integrated Animal Healthcare company with three state of the art manufacturing facilities. The Company's API business is characterized by new product development capability, best-in-class infrastructure, wide product basket and long term relationships with most of the global animal health companies. In the formulations space, Alivira has established business presence in India, Turkey, Africa, MENA and South East Asia. It has close to 200 dosage forms focused towards production animals produced in GMP compliant facilities in Turkey and India.

Alivira's long term vision is to become a global powerhouse for animal health built on a platform of superior quality and compliance.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has nine manufacturing facilities based in India and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

For Queries, please contact

Kannan P R

Chief Financial Officer
Tel: +91 80 67840327
Kannan.pr@sequent.in

Ankit Gupta

Christensen Investor Relations
Tel : +91 22 42150210
ankitgupta@christensenir.com

Registered Office

SeQuent Scientific Limited
301/A, 'Dosti Pinnacle',
Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W),
Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code: 512529

ISIN: INE807F01019

REUTERS: SEQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Sequent Scientific Limited


Preetham Hebbbar
Company Secretary

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	Description	
1.	Name of the Target entity, details in brief such as size, turnover etc.	INTERCHANGE VETERINÁRIA INDÚSTRIA E COMÉRCIO S.A.	
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	No	
3.	Industry to which Target entity being acquired belongs	Manufacturing and Development of Veterinary Products	
4.	Objects and effects of acquisition	Foray into Brazil, the third largest Veterinary market.	
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Approval required from the competent courts in Brazil	
6.	Indicative time period for completion	Expected to be completed by first quarter of FY 17	
7.	Nature of consideration	Cash	
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	70% of Total Voting Capital	
9.	Cost of acquisition or the price at which the shares are acquired	USD 3.6 Mio (approximately INR 250 Mn)	
10.	Brief background about entity acquired in terms of:		
a.	Products/line of business acquired	Interchange, operating under the trade-name Evance is amongst the 'Top 10' Brazilian Companies operating in the veterinary health space with a focus on poultry and swine segments	
b.	Date of incorporation	23/02/1978	
c.	History of last 3 years turnover	Financial year	Turnover (in BRL Mn)
		2015	21.0
		2014	14.2
		2013	11.3
d.	Country in which the acquired entity has presence	Brazil	
e.	Any other significant information	Step down subsidiary in Brazil of Alivira Animal Health Limited, Ireland, a wholly owned subsidiary of the Company, will do the acquisition.	

For Sequent Scientific Limited


Preetham Hebbar
Company Secretary